Premium
Systemic antimicrobials adjuvant to periodontal therapy in diabetic subjects: a meta‐analysis
Author(s) -
Grellmann Alessandra Pascotini,
Sfreddo Camila Silveira,
Maier Juliana,
Lenzi Tathiane Larissa,
Zanatta Fabricio Batistin
Publication year - 2016
Publication title -
journal of clinical periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.456
H-Index - 151
eISSN - 1600-051X
pISSN - 0303-6979
DOI - 10.1111/jcpe.12514
Subject(s) - medicine , bleeding on probing , meta analysis , confidence interval , scaling and root planing , randomized controlled trial , antimicrobial , adjuvant therapy , adjuvant , antibiotics , dentistry , gastroenterology , periodontitis , chronic periodontitis , chemotherapy , biology , chemistry , organic chemistry , microbiology and biotechnology
Abstract Background Adjuvant antibiotics have been suggested to improve periodontal therapy in diabetic subjects. Aim The aim of this study was to systematically review randomized clinical trials assessing systemic antimicrobial use adjuvant to scaling and root planing ( SRP ) versus SRP alone in diabetic subjects. Material and Methods The PubMed, Cochrane Central Register of Controlled Trials, EMBASE , TRIP , Web of Science and LILACS databases and the grey literature were searched through May 2015. Of 2534 potentially eligible studies, 13 were included in the systematic review. Weighted mean differences ( WMD s) in probing depth ( PD ) reduction and clinical attachment level ( CAL ) gain (primary outcomes), and plaque index ( PI ) and bleeding on probing ( BOP ) reductions, were estimated using a random effect model. Results The WMD in PD reduction [−0.15 mm, n = 11, p = 0.001, 95% confidence interval ( CI ) −0.24, −0.06] favoured antibiotic use. WMD s in CAL gain, PI and BOP reductions (−0.14 mm, n = 9, p = 0.11, 95% CI −0.32, 0.03; 4.01%, n = 7, p = 0.05, 95% CI −0.04, 8.07; and −1.91%, n = 7, p = 0.39, 95% CI −6.32, 2.51 respectively) did not favour adjunctive antibiotic use. Conclusion Adjunctive therapy may improve the efficacy of SRP in reducing PD in diabetic subjects.